By revealing metabolic vulnerabilities in fibrolamellar cancer, the research opens the door to targeted therapies that could ...
A preclinical study by researchers at The University of Texas MD Anderson Cancer Center, published in Cell, details a ...
Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have identified a molecule on the surface of cells that could be a promising therapeutic target against cancer.
Scientists know that colorectal cancer cells require large amounts of iron and that as cancer becomes more aggressive, the ...
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for ...
(NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE ® (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the ...
Adrian Toh works, travels, hits the gym and even has a six-pack. Meeting him, you wouldn't think that he's been fighting ...
A preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Cell, details a ...
The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or ...
MedPage Today on MSN
Nature Retracts Cancer Study Linking Treatment Timing to Survival
Editors "no longer have confidence in the integrity of the results" ...
For Riyaz Khan, a 32-year-old cancer patient from Srinagar, Kashmir, the anxiety of battling the disease has been made worse ...
After a four-month investigation, Nature Medicine has decided to pull a viral study that linked early-day PD-1/chemo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results